CARISE EDWARDS: Open Payments
NPI 1023713609 · ENCINITAS, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,276 in 55 payments from 17 companies in 2025. Trend: 2023 $564 · 2024 $1,066 · 2025 $1,276
Food & beverage: $1,276
| Company | Payments | Amount |
|---|---|---|
| Novartis Pharmaceuticals Corporation | 11 | $244 |
| PFIZER INC. | 11 | $174 |
| Edwards Lifesciences Corporation | 1 | $173 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 4 | $100 |
| Alnylam Pharmaceuticals Inc. | 5 | $94 |
| Daiichi Sankyo Inc. | 4 | $89 |
| Amgen Inc. | 4 | $69 |
| AstraZeneca Pharmaceuticals LP | 3 | $60 |
| E.R. Squibb & Sons, L.L.C. | 3 | $59 |
| HEARTFLOW, INC. | 1 | $53 |
Products named: LEQVIO, SAPIEN 3 Ultra RESILIA, ELIQUIS, JARDIANCE, AMVUTTRA, INJECTAFER, Repatha, FFRct.
Industry payments across CA — which companies pay providers there.
